Physician profile
Michael A Bharier
NPI 1336145135
$5,976.88
in general payments reported to CMS, 2019-2025
27 companies · $1,153 in 2025
The $1,153 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $572 · 2021: $813 · 2022: $712 · 2023: $700 · 2024: $1,144 · 2025: $1,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,997.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,065.75 | 2019-2025 | Rinvoq, Skyrizi |
| Leo Pharma INC. | $640.03 | 2019-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $483.26 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $422.40 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $403.80 | 2019-2024 | Siliq, Targretin |
| Amgen INC. | $254.95 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $242.35 | 2019-2025 | Winlevi, Absorica Ld |
| Lilly USA, LLC | $214.60 | 2019-2025 | Ebglyss, Taltz |
| Janssen Biotech, INC. | $172.84 | 2021-2024 | Tremfya, Stelara, Remicade |
| Incyte Corporation | $172.37 | 2021-2023 | Opzelura |
| Ucb, INC. | $139.74 | 2019-2022 | |
| Galderma Laboratories, L.P. | $113.94 | 2023-2025 | Nemluvio, Oracea, Aklief |
| Organon LLC | $89.68 | 2025 | Vtama |
| Kyowa Kirin, INC. | $75.94 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $74.39 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $74.21 | 2019-2024 | |
| Dermira, INC. | $61.59 | 2019-2020 | |
| Dermavant Sciences, INC. | $56.14 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $53.88 | 2024 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $33.91 | 2024 | Dupixent |
| Vyne Pharmaceuticals INC. | $27.68 | 2020 | |
| Verrica Pharmaceuticals INC. | $24.83 | 2023 | Ycanth |
| Merz North America, INC. | $24.16 | 2023 | Xeomin |
| Almirall LLC | $20.08 | 2019 | |
| Prugen, INC. Pharmaceuticals | $15.05 | 2020 | |
| Celgene Corporation | $10.92 | 2019 | |
| Biofrontera INC. | $8.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bharier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.